Back to results
US 2012/0258995 A1Published application
New Indolinone Protein Kinase Inhibitors
AssigneeBeta Pharma, Inc.
InventorsDon Zhang, Guojian Xie
Life of this patent
Estimating the term…
Abstract
The present invention relates to new indolinone compounds and their pharmaceutically acceptable salts and prodrugs for treating and preventing VEGFR related cellular disorders such as cancer.
Claims20
A compound of Formula (I):
- and its pharmaceutically acceptable salts or prodrugs;
- wherein R1 is selected from the group consisting of F, Cl, Br, CF3, CCl3, CN, SO2NHR, COR, CONHR and R;
- wherein R2═R;
- wherein X═CH or CR;
- wherein Y is O, NH or NR;
- wherein n=2-4;
- wherein R is H, alkyl, aryl, alkoxy or aryloxy.
4 more elements
A compound of formula II:
- and its pharmaceutically acceptable salts or prodrugs thereof.
A method of treating or preventing a disorder related to VEGFR.
Dependencies are inferred from the claim text.